Endo Announces Executive VP, Chief Commercial Officer Appointment

Endo announced the appointment of Domenic Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics, effective immediately.

Ciarico will lead commercial strategy and execution for Endo's Generics Pharmaceutical and Sterile Injectable businesses which are marketed and sold under the Par Pharmaceutical brand. He will report to Paul Campanelli, President and Chief Executive Officer, and will join the company's Executive Leadership Team. Most recently, Ciarico served as Senior Vice President and General Manager of Par Sterile Products where he was responsible for all aspects of the U.S. sterile product business which delivered double-digit growth under his leadership. Ciarico succeeds Tony Pera, President, Par Pharmaceutical, who announced his retirement in April 2019.

"Domenic brings a deep knowledge of the healthcare industry, a clear focus on customer needs, and a proven track record of successful execution. Since joining Endo, he has successfully led our Sterile Injectables segment and driven growth," said Campanelli. "I am confident he will continue to build upon the company's solid foundation in generics and strengthen our ability to bring quality medicines to patients."

"I'm very excited to lead such a talented team as we continue to be focused on building our portfolio and capabilities for the future," said Ciarico. "We are proud to serve as a reliable, quality supplier to our customers and look forward to building upon these trusted relationships to best serve patients."

Prior to joining Endo, Ciarico spent 20 years with AmerisourceBergen (ABC). At ABC, he held several roles of increasing responsibility, including Senior Vice President of Health Systems, leading health systems sales and commercial strategy.  Prior to that, he was Group Vice President, managing three of ABC's service businesses, including American Health Packaging, Pharmacy Healthcare Solutions and AmerisourceBergen Technology Group. Ciarico holds a B.S. degree as well as an M.B.A. from The Ohio State University.

"I want to also acknowledge the dedication and accomplishments of Tony Pera," Campanelli said. "Tony has been a strategic member of my leadership team for the past five years, substantially grew our Sterile Injectables business and was critical to the repositioning of our Generic Pharmaceutical business through prudent product selection during a period of tremendous change and customer consolidation. On behalf of myself and the board of directors, we would like to wish him all the best in his retirement."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com